Rhythm Pharmaceuticals (RYTM) Stifel 2024 Healthcare Conference summary

Company overview and therapeutic focus

• Focuses on therapies targeting the melanocortin-4 pathway, crucial for satiety and energy expenditure regulation.

• First product approved in 2020 for rare genetic obesity, followed by a 2022 approval for Bardet-Biedl syndrome, now launched globally.

• Unexpectedly strong results in hypothalamic obesity (HO) patients, including those with acquired hypothalamic injury.

• Lead drug, setmelanotide, acts as an analog of alpha-melanocyte-stimulating hormone, functioning as hormone replacement.

Epidemiology and patient identification

• Estimated 5,000–10,000 HO patients in the U.S., with potential for higher numbers as awareness and diagnosis improve.

• Many HO cases remain unrecognized, especially those resulting from trauma or radiation, not just tumors.

• Congenital HO is clinically diagnosed, not typically identified through genetic screening.

• Early literature underestimated obesity as a disease, leading to underdiagnosis in congenital syndromes.

Clinical data and trial updates

• Phase 2 data showed consistent response to setmelanotide in both pediatric and adult HO patients, with significant weight loss at 1, 3, and 6 months.

• French real-world data confirmed efficacy in adults, even years after injury.

• Ongoing Phase 3 trial is 90% powered for a 12% placebo-adjusted difference; a congenital HO sub-study is being added.

• Sub-study amendment is under FDA review; not a registrational study, but leverages existing infrastructure.

• About 25% of trial participants have prior GLP-1 exposure; 10% are currently on GLP-1s, but must be weight-stable before entry.